Biomarker guided PARP inhibitor maintenance improves outcomes in ovarian cancer meta analysis of phase 3 trials

Prolgolimab plus chemotherapy improves long term survival in advanced nonsquamous NSCLC

Extended interval tarlatamab dosing shows consistent clinical activity in previously treated SCLC

Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC

JS207 plus chemotherapy enables surgery and deep pathological responses in unresectable NSCLC

Bladder cancer updates from the first half of 2026

Zoldonrasib plus daraxonrasib targets KRAS G12D in metastatic pancreatic cancer with promising early results

Therapeutic mammoplasty: An advanced oncoplastic breast surgery technique

Zolbetuximab plus chemo in CLDN18.2-positive metastatic pancreatic cancer does not improve OS

Talquetamab plus daratumumab with or without pomalidomide improves PFS in r/r multiple myeloma

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

The evolving treatment landscape in immune thrombocytopenia